Recently published White Paper provides insights on the status of clinical utility of rapid molecular testing for UTI

PRESS RELEASE

THE DARK REPORT
21806 Briarcliff Dr.
Spicewood, TX 78669
512-264-7103 o
512-264-0969 f

FOR IMMEDIATE RELEASE

Media Contact: Liz Carey
lcarey@darkreport.com

AUSTIN, Texas (July 16, 2020) – Urinary tract infection (UTI) is the second most common type of infection in the US, accounting for 10.5 million office visits per year and 50 percent of all Medicare hospital admissions. UTI is among the most common cause of bacterial infections in long-term care facility residents.

“Effective treatment of a UTI is reliant upon the accurate identification of the pathogens and the correct choice of antibiotics,” stated Robert L. Michel, Editor-in-Chief of The Dark Report. “And although culture-based clinical laboratory testing methods remain the gold standard for diagnosing UTI in both research and clinical laboratories, the clinical utility of such methods continues to be called into question.”

To provide insights on the status of clinical utility of rapid molecular testing for UTI, describe settings where molecular testing for UTI is of high value to improving outcomes, and detail experiences of successful early adopters of this technology, The Dark Report is offering a recently published White Paper, “Molecular Testing for Urinary Tract Infection (UTI): 2020 Update on Clinical Utility and Reimbursement Trends.Published by Dark Daily, it is available free to laboratory professionals as a PDF download.

The White Paper provides illuminating insights regarding:

  • Why a large number of Gram-negative and especially Gram-positive organisms cannot grow in typical culture-based testing conditions, leading to false negatives and missed organisms in a polymicrobial UTI
  • A comparison study of traditional urine culture testing to multiplex polymerase chain reaction (PCR) molecular testing, run in parallel, showing that the molecular method found six additional polymicrobial cases for every one found using urine cultures
  • How, in addition to higher detection rates, PCR can provide results in as little as 6 hours, and may facilitate more appropriate and efficacious treatment that improves clinical care and outcomes
  • Why insurers and other payers are now acknowledging molecular diagnostic testing, which includes deoxyribonucleic acid-(DNA) or ribonucleic acid-(RNA) based analysis

Molecular tests are becoming more routine as diagnostic tools, with many now covered by Medicare and commercial insurers. Advantages of molecular tests based on PCR technology include their ability to identify uropathogens traditionally missed by culture-based tests. This White Paper demonstrates how, driven by urgent, unmet analytical and clinical care needs, the adoption of the rapid molecular test—particularly RT-PCR for urinary tract infection control and treatment—has important implications.

Molecular Testing for Urinary Tract Infection (UTI): 2020 Update on Clinical Utility and Reimbursement Trends is part of the Dark Daily growing library of White Papers and other information resources tailored specifically for the needs of laboratory administrators, lab managers, pathologists, and lab industry consultants.

For additional information, Contact: Liz Carey, lcarey@darkreport.com

About The Dark Intelligence Group
Established in 1995, The Dark Intelligence Group is the leading source of exclusive business intelligence for laboratory CEOs, COOs, CFOs, Pathologists and senior industry executives. It is widely recognized by leaders in laboratory medicine and diagnostics. The Dark Intelligence Group produces the famous Executive War College on Laboratory and Pathology Management every spring, which showcases innovations by the nation’s and globe’s leading laboratory organizations., and Dark Daily — a free e-briefing intelligence service, read worldwide by thought leaders in laboratory and pathology management. Other well-known conferences conducted by TDIG are Lab Quality Confab (on the use of Lean and Six Sigma methods in labs and hospitals), Executive Edge bi-annually in Canada, and The Business of Pathology bi-annually in Australia.

-end-